Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziresovir TQT Study in Healthy Subjects
NCT06591845Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ziresovir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Ark Biosciences. Primary endpoint: Change from baseline QTcF. Started Sep 2024; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06591845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591845.